Abstract
Psoriasis and psoriatic arthritis are debilitating inflammatory immunemediated diseases which are chronic in nature and often require lifelong attention. Traditional therapies used to combat these diseases lack sufficient long-term efficacy and are associated with a number of toxicities. Failing to adequately satisfy both patients and physicians, traditional therapies have proven insufficient and have left few options. Etanercept is a tumor necrosis factor (TNF) antagonist that reduces elevated TNF levels by competitively binding to both TNF-α and TNF-β and inhibiting the proinflammatory cascade. Providing a valuable treatment option alone, etanercept can also be effectively administered in conjunction with traditional treatments. Etanercept is self administered by subcutaneous (SC) injection, making treatment less of a burden for patients by eliminating the need for frequent office visits and laboratory testing. Etanercept is approved in the US for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Keywords: Anti-TNF, Enbrel®, Etanercept, Psoriatic arthritis, Psoriasis
Reviews on Recent Clinical Trials
Title: Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis
Volume: 1 Issue: 3
Author(s): Brian S. Fuchs and Suhail Hadi
Affiliation:
Keywords: Anti-TNF, Enbrel®, Etanercept, Psoriatic arthritis, Psoriasis
Abstract: Psoriasis and psoriatic arthritis are debilitating inflammatory immunemediated diseases which are chronic in nature and often require lifelong attention. Traditional therapies used to combat these diseases lack sufficient long-term efficacy and are associated with a number of toxicities. Failing to adequately satisfy both patients and physicians, traditional therapies have proven insufficient and have left few options. Etanercept is a tumor necrosis factor (TNF) antagonist that reduces elevated TNF levels by competitively binding to both TNF-α and TNF-β and inhibiting the proinflammatory cascade. Providing a valuable treatment option alone, etanercept can also be effectively administered in conjunction with traditional treatments. Etanercept is self administered by subcutaneous (SC) injection, making treatment less of a burden for patients by eliminating the need for frequent office visits and laboratory testing. Etanercept is approved in the US for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Export Options
About this article
Cite this article as:
Fuchs S. Brian and Hadi Suhail, Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250131
DOI https://dx.doi.org/10.2174/157488706778250131 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cell Therapies for Intervertebral Disc Degeneration: Immune Privilege Reinforcement by Fas/FasL Regulating Machinery
Current Stem Cell Research & Therapy Burden of Multidrug Resistant Mycobacterium tuberculosis Among New Cases in Al-Madinah Al-Monawarah, Saudi Arabia
Infectious Disorders - Drug Targets Macrolides as Immunomodulatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents MCM-41-SO3H as an Advanced Nanocatalyst for the Solvent-Free Synthesis of N-aryl-2-amino-1,6-naphthyridine Derivatives
Current Nanoscience Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy The Functional Impact of Alternative Splicing and Single Nucleotide Polymorphisms in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) In-silico & In-vitro Identification of Structure-Activity Relationship Pattern of Serpentine & Gallic Acid Targeting PI3Kγ as Potential Anticancer Target
Current Cancer Drug Targets Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Ginsenoside Rb1 Directly Scavenges Hydroxyl Radical and Hypochlorous Acid
Current Pharmaceutical Design Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes
CNS & Neurological Disorders - Drug Targets Evidence that Pregnancy Specific Glycoproteins Regulate T-Cell Function and Inflammatory Autoimmune Disease During Pregnancy
Current Drug Targets - Inflammation & Allergy A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition
Current Topics in Medicinal Chemistry Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design The Capability to Forecast Response to Therapy with Regard to The Time and Intensity of The Inflammatory Process in vitro in Dermal Fibroblasts Induced by IL-12
Current Pharmaceutical Biotechnology